<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123811</url>
  </required_header>
  <id_info>
    <org_study_id>GC-CIF-2005</org_study_id>
    <nct_id>NCT01123811</nct_id>
  </id_info>
  <brief_title>Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer</brief_title>
  <acronym>GC-CIF-2005</acronym>
  <official_title>An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the current promising results with irinotecan and cetuximab in patients with
      recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in
      gastric cancer , the present clinical study to evaluate the overall response rate, the time
      to progression and the overall survival of the combined treatment of cetuximab and irinotecan
      and 5-FU in patients with esophagogastric cancer is urgently needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab will be analysed with biological markers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Adenocarcinoma of Stomach or Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>Cetuximab IF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with combination of Cetuximab and Irinotecan 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab IF</intervention_name>
    <description>Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36</description>
    <arm_group_label>Cetuximab IF</arm_group_label>
    <other_name>na-folinat oncofolic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Signed and dated informed consent before the start of specific protocol procedures;

          -  Histologically proven gastric adenocarcinoma including adenocarcinoma of the
             esophagogastric junction or Barrett carcinoma (adenocarcinoma of lower oesophagus);

          -  Measurable metastatic disease according to the RECIST criteria. If locally recurrent
             disease, it must be associated with at least one measurable lymph node (&gt; 20 mm by CT
             scan or &gt; 10 mm with spiral CT);

          -  Age: 18-75 years;

          -  ECOG Performance Status 0-2

          -  Life expectancy &gt; 12 weeks;

          -  Adequate hematological, hepatic and renal functions: ANC

             ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L; hemoglobin ≥ 10g/dl; creatinine ≤ 2 x UNL;
             total bilirubin ≤ 3 x UNL, ASAT (SGOT) and ALAT (SGPT) ≤ 3 × UNL; in case of liver
             metastases: total bilirubin ≤ 5 x UNL, ASAT (SGOT) and ALAT (SGPT) ≤ 5 × UNL;

          -  At least 4 weeks from surgery;

          -  Recovery from side effects of any prior therapy;

          -  Able to comply with scheduled assessments and with management of toxicity.

          -  If of childbearing potential, willingness to use effective contraceptive method for
             the study duration and 2 months post-dosing.

        Exclusion Criteria:

          -  Other tumor type than adenocarcinoma (e.g., leiomyosarcoma, lymphoma) or a second
             cancer except in patients with squamous or basal cell carcinoma of the skin or
             carcinoma in situ of the cervix which has been effectively treated. Patients
             curatively treated and disease free for at least 5 years will be discussed with the
             sponsor before inclusion;

               -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
                  indicated in the study protocol;

               -  Any prior palliative chemotherapy, adjuvant (and/or neoadjuvant) chemotherapy or
                  radiotherapy ;

               -  Concurrent treatment with any other anti-cancer therapy;

               -  Patients with known brain or leptomeningeal metastasis;

               -  Hypercalcemia not controlled by bisphosphonates;

               -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive
                  intestinal resection (&gt; hemicolectomy or extensive small intestine resection with
                  chronic diarrhea), Crohn's disease, ulcerative colitis;

               -  Other serious illness or medical conditions:

          -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months
             prior to study entry; congestive heart failure NYHA grade 3 and 4;

          -  Current history of chronic diarrhea;

          -  History of significant neurologic or psychiatric disorders including dementia or
             seizures;

          -  Active uncontrolled infection;

          -  Active disseminated intravascular coagulation;

          -  Other serious underlying medical conditions which could impair the ability of the
             patient to participate in the study;

               -  Known deficit in DPD

               -  Contraindications to the use of atropine;

               -  Concomitant or within a 4-week period administration of any other experimental
                  drug under investigation;

               -  Pregnant or lactating women;

               -  Previous exposure to monoclonal antibodies, signal transduction inhibitors or
                  EGFR pathway targeting therapy;

               -  Known allergic/hypersensitivity reaction to any of the components of the
                  treatment;

               -  Known drug abuse/alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Moehler, Md Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg Univetsity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Städtische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg, Medizinische Klinik I</name>
      <address>
        <city>Ludwigsburg</city>
        <state>Baden-Württemberg</state>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Abt. Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der technischen Universität München, III. Medizinische Klinik: Hämatologie / Onkologie</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Abteilung Gastroenterologie, Hepatologie und Endokrinologie</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Essen, Innere Klinik und Poliklinik - Tumorforschung</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte / Evang. Huyssens-Stiftung, Klinik für Innere Medizin I und Internistische Onkologie / Hämatologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital Recklinghausen, Medizinische Klinik I</name>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg-Universität, I. Medizinische Klinik u. Poliklinik</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Benjamin Franklin, Medizinische Klinik I</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>May 12, 2010</last_update_submitted>
  <last_update_submitted_qc>May 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>M Moehler</name_title>
    <organization>Johannes Gutenberg University Mainz</organization>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>esophagogastric junction cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

